Bussiness Ideas

Biotech Wallah Pvt. Ltd. is at the forefront of deep tech, artificial intelligence, biotechnology, and healthcare, developing an AI-powered platform aimed at revolutionizing drug discovery. The current drug discovery process is plagued by significant challenges: it's incredibly slow, taking 10-15 years and over $2 billion to bring a single drug to market, with a high failure rate of around 90% in clinical trials due to poor early validation. Existing tools are fragmented and siloed, making the workflow inefficient. Furthermore, small and medium-sized enterprises (SMEs), startups, and academic labs face substantial access barriers due to the high cost of AI-driven platforms, and biomedical data handling presents compliance and privacy issues. Biotech Wallah’s solution is an innovative, end-to-end SaaS platform that automates the entire drug discovery process, from disease-gene prioritization to virtual clinical trials. This multi-agent workflow integrates crucial steps like omics analysis, structure prediction, molecule generation, docking, ADMET, synthesis, and trial simulation into a single, unified system. Designed to be affordable and scalable, their cloud-based platform specifically targets startups, universities, and biotech labs, democratizing access to advanced drug discovery tools. A key differentiator is the built-in blockchain-powered data curation, ensuring secure, anonymized, and regulatory-compliant use of biomedical datasets. The platform also offers explainable AI insights, aiming to reduce drug discovery time and cost by up to 70%, addressing the "black-box" problem often associated with AI in healthcare. The market opportunity is substantial, with the global AI in drug discovery market projected to reach $25-30 billion by 2030, and the Indian market estimated at $2-3 billion. Biotech Wallah plans to generate revenue through B2B SaaS subscriptions, wholesale access for incubators and hospitals, enterprise projects, and data licensing. Their go-to-market strategy involves academic and research partnerships, pilot projects with pharma and CROs, and leveraging incubators and accelerators. With a strong team experienced in biotech and AI from institutions like Harvard and IITs, and initial traction including a $5,000 innovation grant, Biotech Wallah is poised to disrupt the drug discovery landscape, seeking $100,000 in funding to further develop their platform and expand operations.

Show More

Startup Teams

• 1 Isarar siddique (Director)
• 2 Arshi Niyaz (Director)

Incubation Details

Not Incubated